Efficacy News and Research

RSS

Treatment of Schizophrenia receives notice of intention to grant a European patent

BioLineRx (NASDAQ:BLRX)(TASE:BLRX), a biopharmaceutical development company, announced today that it has received from the European Patent Office a notice of intention to grant a European patent claiming the salt of BL-1020, a first-in-class orally available treatment for schizophrenia.

9 Jul 2012

JRD receives FDA priority review designation for XARELTO sNDAs to treat PE, DVT

Janssen Research & Development, LLC (Janssen R&D) announced today the U.S. Food and Drug Administration (FDA) has assigned a priority review designation to the supplemental New Drug Applications (sNDAs) filed on May 2, 2012 for XARELTO (rivaroxaban), an oral anticoagulant, seeking new indications to treat patients with deep vein thrombosis (DVT), pulmonary embolism (PE), and to prevent recurrent DVT and PE.

9 Jul 2012

PsiOxus closes Series B round of equity financing

PsiOxus Therapeutics, Ltd. announced that it has closed a Series B round of equity financing totaling £22 million ($34 million).

9 Jul 2012

Ampio announces results from Optina trial on DME

Ampio Pharmaceuticals, Inc., a biopharmaceutical company developing innovative proprietary drugs for inflammation, eye disease, kidney disease, CNS disease, metabolic disease and male sexual dysfunction and conducting clinical trials on its three lead drugs (Ampion, Optina & Zertane), announced the significant results from their further analysis of its Optina trial on DME.

9 Jul 2012

AHF calls for reasonable pricing of Gilead’s Quad AIDS drug

Today AIDS Healthcare Foundation, in response to recent press reports regarding drug manufacturer Gilead Sciences, Inc.'s new four-drug HIV/AIDS pill, known as the "Quad," renewed its call for company to price the drug reasonably, particularly in light of the fact that it represents only a marginal improvement over existing medications.

7 Jul 2012

Novel biomimetic strategy can dissolve blood clots before they cause serious damage or even death

Researchers at the Wyss Institute for Biologically Inspired Engineering at Harvard University have developed a novel biomimetic strategy that delivers life-saving nanotherapeutics directly to obstructed blood vessels, dissolving blood clots before they cause serious damage or even death.

6 Jul 2012

Robert Wood Johnson Foundation, AJPM introduce Childhood Obesity Challenge

The American Journal of Preventive Medicine (AJPM) and the Robert Wood Johnson Foundation have announced the launch of the Childhood Obesity Challenge, a competition that aims to promote creative and innovative solutions to childhood obesity outside the standard framework of scientific research publications.

6 Jul 2012

Scientists use antibody injections to rapidly reverse onset of Type I diabetes in mice

Scientists at the University of North Carolina School of Medicine have used injections of antibodies to rapidly reverse the onset of Type I diabetes in mice genetically bred to develop the disease. Moreover, just two injections maintained disease remission indefinitely without harming the immune system.

6 Jul 2012

Anti-cancer activity of HuCAL antibody revealed by new data from OncoMed

MorphoSys AG's (FSE: MOR; Prime Standard Segment, TecDAX) partner OncoMed Pharmaceuticals today announced that Proceedings of the National Academy of Sciences of the United States of America (PNAS) has published online data demonstrating the potent anti-cancer activity of OMP-18R5, a HuCAL antibody targeting the Wnt pathway, in multiple preclinical human tumor models. OMP-18R5 is currently in Phase 1 clinical testing.

5 Jul 2012

Intense war against malaria outlined by two studies in The American Journal of Tropical Medicine and Hygiene

A pair of provocative studies in the July 2012 issue of The American Journal of Tropical Medicine and Hygiene (AJTMH) provides a window into the intense ground war now underway against malaria.

4 Jul 2012

Shingles vaccine may not increase risk of varicella in people with auto-immune diseases

New research from the University of Alabama at Birmingham casts doubt on the long-standing belief that the vaccine for shingles should not be given to patients taking biologics for auto-immune diseases such as rheumatoid arthritis.

4 Jul 2012

IRIN examines antibiotic resistance, efforts to discover new drugs

IRIN examines a global increase in resistance to antibiotics, writing, "Almost one in every five deaths worldwide occurs as a result of infection, but many bacterial illnesses will become incurable as the efficacy of current antibiotic drugs wanes, according to the World Health Organization (WHO)."

3 Jul 2012

Deleting a single gene results in autism-like behavior

Deleting a single gene in the cerebellum of mice can cause key autistic-like symptoms, researchers have found. They also discovered that rapamycin, a commonly used immunosuppressant drug, prevented these symptoms.

2 Jul 2012

ImmunoCellular to expand ICT-107 Phase IIb trial on GBM

ImmunoCellular Therapeutics, Ltd., a clinical stage biotechnology company that is focused on developing new immune-based products to treat cancer, announced today that it will expand its current Phase IIb trial of ICT-107 from 102 to up to 123 patients with glioblastoma multiforme (GBM) and who are HLA-A1/A2 positive.

2 Jul 2012

Three-step clinical pathway for CAP reduces length of hospital stay

A three-step pathway helps to reduce the duration of intravenous antibiotic treatment in hospitalized patients with community-acquired pneumonia, show study findings published in the Archives of Internal Medicine.

2 Jul 2012

Cerulean commences dosing in CRLX101-Avastin combination study for metastatic renal cell carcinoma

Cerulean Pharma Inc., a leader in developing dynamically tumor-targeted nanopharmaceuticals, today announced that the first patient has been dosed in a Phase 1b/2a study of its lead product candidate, CRLX101, in combination with Avastin, in metastatic renal cell carcinoma (mRCC) patients. The company also announced the completion of enrollment of its randomized Phase 2 study in advanced non-small cell lung cancer.

2 Jul 2012

Enrollment complete in Cerulean CRLX101 Phase 2 study for non-small cell lung cancer

Cerulean Pharma Inc., a leader in developing dynamically tumor-targeted nanopharmaceuticals, today announced that it has completed enrollment of a randomized Phase 2 study of its lead candidate, CRLX101, in advanced non-small cell lung cancer (NSCLC). The company also announced that it has dosed the first patient in a second tumor type.

2 Jul 2012

Janssen seeks accelerated FDA approval for bedaquiline to treat MDR-TB

Janssen Research & Development, LLC today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking accelerated approval for the use of the investigational drug bedaquiline (TMC207) as an oral treatment, to be used as part of combination therapy for pulmonary, multi-drug resistant tuberculosis (MDR-TB) in adults.

2 Jul 2012

Clinical results for Teva's biologic oncology candidates presented at MASCC/ISOO 2012

Teva Pharmaceutical Industries Ltd. announced today the presentation of clinical results for its biologic oncology candidates, lipegfilgrastim and balugrastim, at the Multinational Association of Supportive Care in Cancer (MASCC)/International Society of Oral Oncology (ISOO) 2012 International Symposium on Supportive Care in Cancer being held in New York June 28-30.

2 Jul 2012

Liraglutide efficacy in Japanese patients “easy” to predict

Liraglutide therapy is an effective alternative to basal-supported oral therapy for some Japanese patients with diabetes, while it is completely ineffective for others, report researchers.

29 Jun 2012

Efficacy News and Research

Treatment of Schizophrenia receives notice of intention to grant a European patent

JRD receives FDA priority review designation for XARELTO sNDAs to treat PE, DVT

PsiOxus closes Series B round of equity financing

Ampio announces results from Optina trial on DME

AHF calls for reasonable pricing of Gilead’s Quad AIDS drug

Novel biomimetic strategy can dissolve blood clots before they cause serious damage or even death

Robert Wood Johnson Foundation, AJPM introduce Childhood Obesity Challenge

Scientists use antibody injections to rapidly reverse onset of Type I diabetes in mice

Anti-cancer activity of HuCAL antibody revealed by new data from OncoMed

Intense war against malaria outlined by two studies in The American Journal of Tropical Medicine and Hygiene

Shingles vaccine may not increase risk of varicella in people with auto-immune diseases

IRIN examines antibiotic resistance, efforts to discover new drugs

Deleting a single gene results in autism-like behavior

ImmunoCellular to expand ICT-107 Phase IIb trial on GBM

Three-step clinical pathway for CAP reduces length of hospital stay

Cerulean commences dosing in CRLX101-Avastin combination study for metastatic renal cell carcinoma

Enrollment complete in Cerulean CRLX101 Phase 2 study for non-small cell lung cancer

Janssen seeks accelerated FDA approval for bedaquiline to treat MDR-TB

Clinical results for Teva's biologic oncology candidates presented at MASCC/ISOO 2012

Liraglutide efficacy in Japanese patients “easy” to predict

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News